Skip to main content

Table 6 Associations between the use of Azathioprine or 6-mercaptopurine and patient and treatment characteristics for patients with Crohn's disease

From: A national survey on the patterns of treatment of inflammatory bowel disease in Canada

Characteristics % reporting Aza/6 MP Odds ratio 95% CI
Sex    
   Male 23.5 Referent  
   Female 23.8 1.0 0.8 to 1.3
Age    
   16–24 45.3 Referent  
   25–40 29.0 0.5 0.3 to 0.8
   41–55 22.3 0.4 0.2 to 0.6
   >55 15.0 0.2 0.1 to 0.4
Disease activity    
   Inactive 19.2 Referent  
   Mild 18.5 1.0 0.7 to1.3
   Moderate 26.6 1.5 1.1 to 2.1
   Severe 38.2 2.6 1.7 to 3.9
Hospitalizations Past 5 Years    
   None 17.4 Referent  
   1 – 2 26.1 1.7 1.3 to 2.2
   > 2 38.8 3.0 2.2 to 4.1
Surgery within the past 2 years    
   No 21.3 Referent  
   Yes 38.0 2.3 1.7 to 3.0
IV Steroids in past 12 months    
   No 22.8 Referent  
   Yes 41.1 2.4 1.5 to 3.7
PO Steroids in past 12 months    
   No 16.6 Referent  
   Yes 37.1 3.0 2.4 to 3.7
Combined family income before taxes ($)    
   < 20,000 27.6 Referent  
   21,000–40,000 18.8 0.6 0.4 to1.0
   41,000–60,000 24.7 0.9 0.5 to1.4
   61,000–80,000 26.9 0.9 0.6 to 1.6
   > 80,000 25.5 0.9 0.6 to 1.4
   Prefer not to answer 21.4 0.7 0.4 to 1.2
Region    
   Maritimes 21.0 Referent  
   Quebec 28.2 1.5 0.9 to 2.5
   Ontario 23.6 1.2 0.7 to 1.9
   Prairies 22.0 1.1 0.6 to 1.8
   West Coast 22.6 1.1 0.6 to 2.0
\